DFSVX
Price
$62.01
Change
-$0.30 (-0.48%)
Updated
Sep 14 closing price
Net Assets
19.54B
RYMVX
Price
$89.75
Change
-$1.05 (-1.16%)
Updated
Sep 14 closing price
Net Assets
6.73M
Interact to see
Advertisement

DFSVX vs RYMVX

DFSVX vs RYMVX Comparison Chart in %
View a ticker or compare two or three
VS
DFSVX vs. RYMVX commentary
Sep 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DFSVX is a Hold and RYMVX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
DFSVX has more cash in the bank: 19.5B vs. RYMVX (6.73M). DFSVX pays higher dividends than RYMVX: DFSVX (1.50) vs RYMVX (0.12). DFSVX was incepted earlier than RYMVX: DFSVX (34 years) vs RYMVX (22 years). RYMVX (1.59) is less costly to investors than DFSVX (0.31). RYMVX is a more actively managed with annual turnover of: 2930.00 vs. DFSVX (7.00). DFSVX has a lower initial minimum investment than RYMVX: DFSVX (0) vs RYMVX (2500). DFSVX annual gain was more profitable for investors over the last year : 24.53 vs. RYMVX (15.76). DFSVX return over 5 years is better than : 50.45 vs. RYMVX (29.41).
DFSVXRYMVXDFSVX / RYMVX
Total Expense Ratio0.311.5420%
Annual Report Gross Expense Ratio0.311.5919%
Fund Existence34 years22 years-
Gain YTD21.62917.434124%
Front LoadN/A5%-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets19.5B6.73M289,877%
Annual Yield % from dividends1.500.121,213%
Returns for 1 year24.5315.76156%
Returns for 3 years59.5541.64143%
Returns for 5 years50.4529.41172%
Returns for 10 years105.41110.1996%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBIOX29.36N/A
N/A
Fidelity Select Biotechnology
NSNRX52.65N/A
N/A
Neuberger Small Cap Growth R3
ETCHX49.63N/A
N/A
Eventide Healthcare & Life Sciences C
MAIJX22.60N/A
N/A
Morgan Stanley Inst Passport ovrs eq R6
JHCQX11.65N/A
N/A
JHancock Fundamental Equity Inc R6